Exploring the Role of Biomarkers for the Diagnosis and Management of Traumatic Brain Injury Patients

Linda Papa
Graduate Medical Education, Orlando Health
Department of Emergency Medicine
University of Florida, College of Medicine
Florida State University, College of Medicine
University of Central Florida, College of Medicine
Orlando Regional Medical Center, Orlando, Florida
USA

1. Introduction

There are an estimated 10 million people affected annually by traumatic brain injury (TBI) across the globe.\(^1\) In the United States, TBI is a major cause of death and disability\(^2\) with about 52,000 annual deaths and 5.3 million Americans impaired by its effects. TBI is a contributing factor to over 30% of all injury-related deaths in the United States and it has been referred to as the silent epidemic of our time.\(^3, 4\) European TBI prevalence data is not consistently reported by each country but it has been estimated that 1.6 million head-injured patients are hospitalized annually in Europe with an incidence rate of about 235 per 100,000. There is an average mortality rate of about 15 per 100,000 and a case fatality rate of about 11 per 100. The TBI severity ratio of hospitalized patients is about 22:1.5:1 for mild vs. moderate vs. severe cases, respectively.\(^5\) According to the World Health Organization, TBI will surpass many diseases as the major cause of death and disability by the year 2020.\(^1\)

Brain injuries can be focal, diffuse or a combination of focal and diffuse. The degree of brain injury depends on the primary mechanism/magnitude of injury, secondary insults and the patient’s genetic and molecular response. Following the initial injury, cellular responses and neurochemical and metabolic cascades contribute to secondary injury.\(^6, 7\) Focal brain injuries include contusions, brain lacerations, and hemorrhage leading to the formation of hematoma in the extradural, subarachnoid, subdural, or intracerebral compartments within the head. Traumatic brain injury represents a spectrum of injury severity. The number, types, and location of lesions as well as the magnitude of overlapping injuries across this spectrum of injury severity are still not clearly described and are challenging to classify.

There are two aspects to injury caused by TBI - the damage caused by the initial impact or insult, and that which may subsequently evolve over the ensuing hours and days referred to as secondary insults. Secondary insults can be mediated through physiologic events which decrease supply of oxygen and energy to the brain tissue or through a cascade of cytotoxic events. These events are mediated by many molecular and cellular processes.
2. The importance of mild and moderate TBI

Research in the field of TBI has long been dominated by research on severe brain injury. However, of the estimated 1.8 million people in the United States who sustain a TBI each year, over 90% will have either a “moderate” (GCS 9-12) or “mild” (GCS 13-15) injury; far outnumbering severe injuries.2-8,9 Moderate TBI comprises over 10% of all TBI and mild TBI over 80%.8 The majority of these patients will present to emergency departments (ED’s) around the country for assessment and treatment.10 The direct medical costs for treatment of TBI in the United States have been estimated at more than $4 billion annually.11 If the costs of lost productivity that result from TBI are added to this then the overall estimated cost is closer to $56.3 billion. Moreover, mild TBI is significantly underdiagnosed and the likely societal burden is therefore even greater.12 Mild and moderate TBI are often difficult to assess and distinguish clinically during the first hours after injury because neurological examinations are of restricted value. The distinction between mild, moderate and severe TBI is initially based on a GCS score and this may be influenced by factors such as perfusion and intoxication from drugs or alcohol, sedative medications, and other distracting injuries.

The term “mild TBI” is actually a misnomer. Individuals who incur a TBI and have an initial GCS score of 13-15 are acutely at risk for intracranial bleeding and diffuse axonal injury.13 Additionally, a significant proportion is at risk for impairment of physical, cognitive, and psychosocial functioning.14-18 Although some patients with mild TBI may be admitted to the hospital overnight, the vast majority are treated and released from emergency departments with basic discharge instructions. Most receive little guidance with respect to follow-up care. This group of TBI patients represents the greatest challenges to accurate diagnosis and outcome prediction. With perhaps no overt signs of acute head injury and a lack of clinical tools to detect the subtle cognitive deficits the patient is considered “unimpaired” and is discharged home and typically left to deal with persisting neurocognitive deficits on their own.19 Accordingly, a significant minority has incomplete recoveries and has outcomes disproportionately worse than would have been predicted by the objective facts of the injury.19,20 The lack of clinical tools to detect the deficits that affect daily function leads to a state of frustration for patients and families that arises out of a failure to understand the nature of the difficulties encountered daily. Treatment protocols for mild TBI have only slowly begun to emerge and are still experimental. The injury is often seen as “not severe” and subsequently therapies have not been aggressively sought for these individuals. Unfortunately, despite the better understanding of the anatomical, cellular and molecular mechanisms of TBI, these advances have not yet yielded significant improvements in treatment. Among the potential barriers to treatment are the heterogeneity of traumatic brain injury, difficulty with stratification of patients by injury severity and lack of early markers of injury.21-24

3. The problem with current assessment of TBI

Prognostic tools for risk stratification of TBI patients are limited in the early stages of injury in the emergency setting for all severities of TBI. Unlike other organ-based diseases where rapid diagnosis employing biomarkers from blood tests are clinically essential to guide diagnosis and treatment, such as for myocardial ischemia or kidney and liver dysfunction, there are no rapid, definitive diagnostic tests for traumatic brain injury. Moreover, the
Exploring the Role of Biomarkers for the Diagnosis and Management of Traumatic Brain Injury Patients

reference standard for TBI is also more difficult to define than say cardiac ischemia. There is no early gold standard for stratification of patients by severity. Currently, diagnosis of TBI depends on a variety of measures including neurological examination and neuroimaging. Neuroimaging techniques such as CT scanning and MRI are used to provide objective information. However, CT scanning has low sensitivity to diffuse brain damage and confers exposure to radiation. MRI can provide information on the extent of diffuse injuries but its widespread application is restricted by cost, the limited availability of MRI in many centers, and the difficulty of performing it in physiologically unstable patients. Additionally, its role in the clinical management of TBI patients acutely has not been established.  

While increasing CT use has reduced hospital admissions, it has also raised concern over unnecessary exposure to ionizing radiation. Although the calculation of projected cancer risk is still controversial, some studies suggest that CT scans of the head may be among the largest contributors to radiation exposure due to the frequency with which they are performed. There is significant consensus that efforts should be made to prevent unnecessary radiation exposure while maintaining quality of care.

4. Challenges to the clinical application of biomarkers

There have been a number of cerebrospinal fluid (CSF) and serum biomarkers evaluated in TBI animal models and in humans. However, many of these candidate biomarkers have failed to exhibit adequate sensitivity and specificity for brain injury, and they have added minimal diagnostic and prognostic information. As a result many are skeptical about the potential of neurotrauma biomarkers to influence future clinical management and clinical trials. This reservation is based on a handful of biomarkers studied using compromised research designs and without the advantage of advancements made in the field of proteomics. Even though the application of proteomics in brain injury is still in its infancy, neuroproteomics is penetrating the field of neurotrauma and brings great potential for improvements in research and patient care. As this technology advances and integrates other technologies such as bioinformatics and neuroimaging, characterization of CNS proteins will occur quickly and many more potential markers will be validated in a shorter timeframe.

Another important challenge in validating biomarkers for TBI will be that traditional outcome measures used to measure injury severity are, in and of themselves, limited. This is true for all severities of injury, and is particularly germane to the less severe injuries where neuroimaging, such as computed tomography (CT), may not demonstrate any obvious pathology. Traditionally, TBI has been separated into three very broad categories: mild, moderate and severe. Unfortunately, this classification scheme fails to capture the spectrum of TBI and the different types of injuries associated with it. The difficulty in classifying injury severity is one which has made clinical trials in the field of TBI challenging. Therapeutic clinical trials for TBI have met with negative results at a cost of over $200 million. These failures have been attributed to a multitude of factors but particularly to the heterogeneity of TBI which makes classification of the different injury types problematic. This heterogeneity, together with the lack of early definitive measures of severity opens the door for using biomarkers as early prognostic indicators. Potentially, biomarkers could provide early outcome measure for clinical trial obtainable much more reliably and economically than conventional neurological assessments, thereby significantly reducing the risks and costs of human clinical trials.
The release of substances and potential biomarkers after an injury is not a static process. Understanding the biokinetic properties of a biomarker will be essential to understanding the release pattern and “optimum” time for measurement. Clinicians and researchers will have to keep in mind that different injury types (for instance, mass lesions versus diffuse injuries) may demonstrate different kinetic parameters and, thus, may produce different quantities of a marker with different peaks and rates of decay. Moreover, secondary insults may also contribute to secondary elevations in a marker, altering its sensitivity and specificity at different time-points.

For markers measured in serum, the level of a biomarker may also reflect the extent of blood brain barrier disruption. Furthermore, extracranial sources of the biomarker may limit its specificity by creating false positives, thus compromising its clinical utility. For instance, the release of a potential CNS marker into the serum from other traumatized tissues or organs would hamper its clinical value in the setting of polytrauma. Another possible situation in which false positive marker values could occur is in the presence of a pre-existing disease state that may alter the metabolism or clearance of the marker, as with kidney or liver disease. Such factors need to be carefully assessed in rigorously designed clinical studies. Future studies should also ensure that adequate control groups are selected for comparison. Ongoing studies by our group are currently being conducted to more fully elucidate the relationships between novel biomarkers and severity of injury and clinical outcomes in all severities of TBI patients. Before clinical application neurochemical markers will have to be rigorously evaluated and the above mentioned challenges taken into consideration.

5. Proteomic techniques in neurobiomarker discovery

Two dimensional gel electrophoresis (2D GE) and mass spectrometry has classically been the gold standard for protein identification. It is an excellent technique for discovering a multitude of proteins and is widely used. However, it requires specialized training and technical expertise. Some of the disadvantages include sample to sample variation, the inability to detect certain classes or sizes of proteins, and the need for many samples and controls.40

There are also non–gel-based mass spectrometry methods for identifying proteins that use high-resolution chromatography to separate complex mixtures of proteins prior to mass spectrometry. Typically the technique uses capillary chromatography for sensitivity and high-resolution mass spectrometry for identification of proteins. There is no need for two-dimensional gel electrophoresis for initial separation and it can analyze a wider range of proteins. However, the technique requires significant expertise and the cost of the materials and equipment to run this technique is much higher.40

Newer proteomic techniques are employing antibody-based methods such as high throughput immunoblotting and antibody panels and/or arrays (ELISA’s). Antibodies are significantly more specific and selective than traditional techniques and allow the detection of proteins amid complex high-protein content biofluids such as serum or plasma.41

Methods of amplifying the signal are under development so that only very small samples will be required for analysis. The drawback of this technique is its reliance on the sensitivity and specificity of the antibodies, and the inability to identify a wide range of proteins because the protein of interest must be pre-selected.

Examples of these techniques will be taken from studies conducted by our group. In two studies published in the Journal of Neurotrauma in 2007 by Pineda et al.42 and in 2009 by
Exploring the Role of Biomarkers for the Diagnosis and Management of Traumatic Brain Injury Patients

Brophy et al.\textsuperscript{43} an immunoblotting technique employing sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was used to measure alpha-spectrin. Quantitative evaluation of intact \textit{aII}-spectrin and its breakdown products (SBDP150, SBDP145 and SBDP120) was performed via computer-assisted densitometric scanning. An example of the ELISA technique is taken from a study published in Critical Care Medicine in 2010 by Papa et al.\textsuperscript{44} that measured Ubiquitin C-terminal hydrolase. In this study samples were measured using a standard UCH-L1 sandwich ELISA where reaction wells were coated with capture antibody and detection antibody was added to wells. The wells were developed with substrate solution and read with a spectrophotometer.

6. Status of biomarker research

Although there are a number of biochemical markers that have been investigated in TBI, our discussion will include the most current and widely studied ones. The most extensively studied among these are glial protein S-100 beta(\textsuperscript{45-55}), neuron-specific enolase (NSE)\textsuperscript{56-63}, and myelin basic protein (MBP)\textsuperscript{41, 59, 64-66}. Although some of these published studies suggest that these biomarkers correlate with degree of injury; conflicting results exist.\textsuperscript{67-75} S100\textsubscript{b} is the major low affinity calcium binding protein in astrocytes\textsuperscript{76} and it is considered a marker of astrocyte injury or death. It can also be found in non-neural cells such as adipocytes, chondrocytes, and melanoma cells.\textsuperscript{77} Elevated serum levels have been associated with increased incidence of post concussive syndrome and impaired cognition.\textsuperscript{78, 79} Other studies have reported that serum levels of S-100\textsubscript{b} are associated with MRI abnormalities and with neuropsychological examination disturbances after mild TBI.\textsuperscript{80, 81} A number of studies have found significant correlations between elevated serum levels of S-100\textsubscript{b} and CT abnormalities.\textsuperscript{82-84} It has been suggested that adding the measurement of S-100B concentration to clinical decision tools for mild TBI patients could potentially reduce the number of CT scans by 30\%.\textsuperscript{84} Other investigators have failed to detect associations between S-100\textsubscript{b} with CT abnormalities.\textsuperscript{67, 85, 86, 87} The vast majority of these clinical studies have employed ELISA to measure levels of S100B. Although S-100\textsubscript{b} continues to be actively investigated and remains promising as an adjunctive marker, its utility as a biochemical diagnostic remains controversial. Some studies have observed high serum S-100\textsubscript{b} levels in trauma patients without head injuries suggesting that it lacks CNS specificity and is released from peripheral tissues.\textsuperscript{88-90}

Neuron specific enolase is one of the five isozymes of the glycolytic enzyme enolase found in central and peripheral neurons and it has been shown be elevated following cell injury.\textsuperscript{91} It has a molecular weight of 78 kDa and a biological half-life of 48 hours.\textsuperscript{92} This protein is passively released into the extracellular space only under pathological conditions during cell destruction. Several reports on serum NSE measurements of mild TBI have been published.\textsuperscript{59, 62, 91, 93} Most of these studies employed an enzyme immunoassay for NSE detection. Many of these studies either contained inadequate control groups or concluded that serum NSE had limited utility as a marker of neuronal damage. Early levels of NSE and MBP concentrations have been correlated with outcome in children, particularly those under 4 years of age.\textsuperscript{64, 65, 94, 95} A limitation of NSE is the occurrence of false positive results in the setting of hemolysis.\textsuperscript{96} A supposedly cleaved form of tau, c-tau, has also been investigated as a potential biomarker of CNS injury. Tau is preferentially localized in the axon and tau lesions are apparently related to axonal disruption.\textsuperscript{97, 98} CSF levels of c-tau were significantly elevated in TBI.
patients compared to control patients and these levels correlated with clinical outcome.\textsuperscript{99, 100} Though levels of c-tau were also elevated in plasma from patients with severe TBI, there was no correlation between plasma levels and clinical outcome.\textsuperscript{101} A major limitation of all of these biomarkers is the lack of specificity for defining neuropathological cascades.

Alpha-II-spectrin (280 kDa) is the major structural component of the cortical membrane cytoskeleton and is particularly abundant in axons and presynaptic terminals.\textsuperscript{102, 103} It is also a major substrate for both calpain and caspase-3 cysteine proteases.\textsuperscript{104, 105} A hallmark feature of apoptosis and necrosis is an early cleavage of several cellular proteins by activated caspases and calpains. A signature of caspase-3 and calpain-2 activation is cleavage of several common proteins such as cytoskeletal αII-spectrin.\textsuperscript{106} In a rat model, mean levels of both ipsilateral cortex (IC) and cerebral spinal fluid (CSF) spectrin breakdown products (SBDP) at 2, 6, and 24 h after two levels of controlled cortical impact (1.0 mm and 1.6 mm of cortical deformation) were significantly elevated by injury using immunoblotting.\textsuperscript{107} Using the same proteomic Western blot technique, levels of spectrin breakdown products (SBDP’s) have been reported in CSF from adults with severe TBI and they have shown a significant relationship with severity of injury and clinical outcome.\textsuperscript{42, 108-113} Following a TBI the axonally enriched cytoskeletal protein α-II-spectrin is proteolyzed by calpain and caspase-3 to signature breakdown products (SBDPs). Calpain and caspase-3 mediated SBDP levels in CSF have shown to be significantly increased in TBI patients at several time points after injury, compared to control subjects. The time course of calpain mediated SBDP150 and SBDP145 (markers of necrosis) differs from that of caspase-3 mediated SBDP120 (marker of apoptosis). Average SBDP values measured early after injury correlated with severity of injury, CT scan findings and outcome at 6 months post injury.\textsuperscript{43}

A promising candidate biomarker for TBI currently under investigation is Ubiquitin C-terminal Hydrolase-L1 (UCH-L1). UCH-L1 was previously used as a histological marker for neurons due to its high abundance and specific expression in neurons.\textsuperscript{114} This protein is involved in the addition and removal of ubiquitin from proteins that are destined for metabolism.\textsuperscript{115} It has an important role in the removal of excessive, oxidized or misfolded proteins during both normal and pathological conditions in neurons.\textsuperscript{116} In initial studies, UCH-L1 was identified as a protein with a two-fold increase in abundance in the injured cortex 48 hours after controlled cortical impact in a rat model of TBI.\textsuperscript{117} Subsequently, a UCH-L1 sandwich enzyme-linked immunosorbent assay quantitatively showed that CSF and serum UCH-L1 levels in rats were significantly elevated as early as 2 hours following both traumatic and ischemic injury.\textsuperscript{118} Clinical studies in humans with severe TBI confirmed, using ELISA analysis, that the UCH-L1 protein was significantly elevated in human CSF\textsuperscript{44}, and was detectable very early after injury and remained significantly elevated for 168 hours post-injury.\textsuperscript{44} Further studies in severe TBI patients have revealed a very good correlation between CSF and serum levels.\textsuperscript{120} Most recently, UCH-L1 was detected in the serum of mild and moderate TBI (MMTBI) patients within an hour of injury.\textsuperscript{121} Serum levels of UCH-L1 discriminated MMTBI patients from uninjured and non-head injured trauma controls and were also able to distinguish mild TBI (concussion patients) from these controls. Most notable was that levels were significantly higher in those with intracranial lesions on CT than those without lesions.\textsuperscript{121}

Glial Fibrillary Acidic Protein (GFAP) is a monomeric intermediate protein found in astroglial skeleton that was first isolated by Eng et al. in 1971.\textsuperscript{122} GFAP is found in white and gray brain matter and is strongly upregulated during astrogliosis.\textsuperscript{123} Current evidence indicates that serum GFAP might be a useful marker for various types of brain damage from
neurodegenerative disorders\textsuperscript{124, 125} and stroke\textsuperscript{126} to severe traumatic brain injury.\textsuperscript{127-131} Recently, Vos et al. described serum GFAP profile in severe and moderate TBI (GCS <12).\textsuperscript{54} In a recent study by our group, GFAP was systematically assessed in human serum following mild and moderate TBI. We confirmed that the GFAP levels were significantly elevated in this population using ELISA analysis, including those with mild TBI. GFAP was able to discriminate TBI patients from uninjured controls. Additionally, serum levels were able to distinguish orthopedic and motor vehicle controls from TBI patients. GFAP was detectable in serum within a few hours of injury and was associated with measures of injury severity including the GCS score and CT lesions.\textsuperscript{132, 133} The present work extends findings from studies in severe TBI to mild and moderate TBI.

Fig. 1. The neuroanatomical locations of the above mentioned biomarkers.

**7. Attributes of an ideal biomarker for TBI**

Research in the field TBI biomarkers has increased exponentially over the last 20 years with most of the publications on the topic occurring in the last 10 years.\textsuperscript{134} During the course of our work in the development of TBI biomarkers, it has become evident that there are a number of key features that a clinically useful biomarker should possess.\textsuperscript{135} An “ideal biomarker” would: 1) demonstrate a high sensitivity and specificity for brain injury; 2) stratify patients by severity of injury; 3) have a rapid appearance in accessible biological fluid; 4) provide information on injury mechanisms; 5) have well defined biokinetic properties; 6) monitor progress of disease and response to treatment; 7) predict functional outcome; 8) be easily measured by widely available, simple techniques.
Clinical researchers have developed methodological standards for developing clinical decision tools in order to ensure the validity of study results. As TBI biomarker research transitions from the bench to the bedside there are a number of important methodological issues that researchers will have to consider as they design their clinical protocols. Since TBI biomarkers are being designed for clinical management, the outcome or diagnosis being examined will need to be clearly defined and clinically important. In order to ensure external validity and the generalizability of the results, study patients will have to be selected without bias and represent a wide spectrum of clinical and demographic characteristics. When interpreting the data, clinical variables that potentially affect outcome will require careful consideration in the analysis. Multivariate statistical and bioinformatics models will also further improve classification of patients and help reduce systematic bias. Another essential consideration will be the examination of biokinetic properties and temporal profiles of the biomarkers as well as systematic comparisons to controls.

8. The potential clinical role of biomarkers

Biochemical markers could help with clinical decision making by elucidating injury severity, injury mechanism(s), and monitoring progression of injury. Temporal profiles of changes in biomarkers could guide timing of diagnosis and treatment. Biomarkers could have a role in management decisions regarding patients at high risk of repeated injury. Accurate identification of these patients could facilitate development of guidelines for return to duty, work or sports activities and also provide opportunities for counseling of patients suffering from these deficits. Repeated mild TBI occurring within a short period (i.e. hours, days, or weeks) can be catastrophic or fatal, a phenomenon termed "second impact syndrome." Acute CT or MRI abnormalities are not usually found after these injuries, but levels of some neurotransmitters remain elevated, and a hypermetabolic state may persist in the brain for several days after the initial injury. During this time the brain appears to be particularly vulnerable to additional TBI, which may result in severe sequelae, including greatly increased cerebral edema and even death. Biomarkers could serve as prognostic indicators by providing information for patients and their families about the expected course of recovery. It opens the door to the initiation of early therapies. Identifying at-risk patients with less apparent TBI or differentiating injury pathology in those with more severe intracranial processes would be tremendously valuable in the management of these patients. For example, in a patient with a normal CT scan or MRI, a biomarker that could predict worsening neurological status or long-term disability would have great clinical utility.

There have been a large number of clinical trials studying potential therapies for traumatic brain injury (TBI) that have resulted in negative findings. Biomarkers measurable in blood would have important applications in clinical research of these injuries. Biomarkers could provide clinical trial outcome measures that are cost-effective and more readily available than conventional neurological assessments, thereby significantly reducing the risks and costs of human clinical trials. Biomarkers that represent highly sensitive and specific indicators of disease pathways have been used as substitutes for outcomes in clinical trials when evidence indicates that they predict clinical risk or benefit. Lack of quickly accessible pathophysiologic information during the post-injury course has made pharmacologic intervention problematic. Biomarkers could provide more timely information on disease progression and the effects of interventions such as drugs and...
surgery. Biomarker measurements could potentially relate the effects of interventions on molecular and cellular pathways to clinical responses. In doing so, biomarkers would provide an avenue for researchers and clinicians to gain a mechanistic understanding of the differences in clinical response that may be influenced by uncontrolled variables. Intoxicated, unconscious, sedated, or polytraumatized patients suspected of having a TBI pose a particular challenge to emergency and trauma physicians. Biomarkers could expedite the evaluation of such patients by providing information on the degree of brain injury prior to neuroimaging. Biomarkers in this setting could also help determine the need for early neurosurgical consultation or transfer to facilities with neurosurgical capabilities.

There are potential military applications as well. Serum biomarkers could help diagnose and/or triage brain injured military servicemen and women. TBI is a leading cause of combat casualty with an estimated 15-20% of all injuries sustained in 20th century conflicts being to the head. America's armed forces are sustaining attacks by rocket-propelled grenades, improvised explosive devices, and land mines almost daily in the recent conflicts in Iraq and Afghanistan. It has been suggested that over 50% of injuries sustained in combat are the result of such explosive munitions including bombs, grenades, land mines, missiles, and mortar/artillery shells. Neuroimaging techniques to diagnose brain injury acutely and other monitoring tools that assess secondary insults are not immediately available in combat zones and such casualties have to be evacuated. Triage and management of brain injured soldiers could be significantly improved if first responders had a quick and simple means of objectively assessing severity of brain injury and of monitoring secondary insults.

There is a unique opportunity to use the insight offered by biochemical markers to shed light on the complexities of the injury process. Accordingly, certain markers could be used as indicators of damage to a particular cell type or cellular process or may be indicative of a particular type of injury. Neuroanatomically, that could include evidence of, say, primary axonal damage versus glial damage. With such heterogeneity the solution may not lie with a single biomarker but more with a complementary panel of markers that may prove useful in distinguishing different pathoanatomic processes of injury.

9. Conclusion

The exploration and validation of biomarkers for TBI using advances in proteomics, neuroimaging, genomics, and bioinformatics must continue. Biomarkers of TBI measured through a simple blood test have the potential to significantly improve the management of TBI patients by providing timely information on the pathophysiology of injury; improving stratification of patients by injury severity; monitoring of secondary insults and injury progression; monitoring response to treatment; and predicting functional outcome. Biomarkers could provide major opportunities for the conduct of clinical research including confirmation of injury mechanism(s) and drug target identification. Ultimately the goal is improve outcome in patients suffering from these injuries.

10. References

[1] Hyder AA, Wunderlich CA, Puvanachandra P, Gururaj G, Kobusingye OC. The impact of traumatic brain injuries: a global perspective. NeuroRehabilitation. 2007;22(5):341-353.
[2] Consensus conference. Rehabilitation of persons with traumatic brain injury. NIH Consensus Development Panel on Rehabilitation of Persons With Traumatic Brain Injury. *Jama.* 1999;282(10):974-983.

[3] Faul M, Xu L, Wald MM, Coronado VG. Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths. In: Services USDoHaH, ed. *Centers for Disease Control and Prevention, National Center for Injury Prevention and Control.* March 2010 ed. Atlanta, GA; 2010.

[4] Hoffman SW, Shesko K, Harrison CR. Enhanced neurorehabilitation techniques in the DVBIC Assisted Living Pilot Project. *NeuroRehabilitation.* 26(3):257-269.

[5] Tagliaferri F, Compagnone C, Korsic M, Servadei F, Kraus J. A systematic review of brain injury epidemiology in Europe. *Acta Neurochir (Wien).* Mar 2006;148(3):255-268; discussion 268.

[6] Graham DI, Adams JH, Nicoll JA, Maxwell WL, Gennarelli TA. The nature, distribution and causes of traumatic brain injury. *Brain Pathol.* Oct 1995;5(4):397-406.

[7] Graham DI, Horsburgh K, Nicoll JA, Teasdale GM. Apolipoprotein E and the response of the brain to injury. *Acta Neurochir Suppl.* 1999;73:89-92.

[8] Yealy DM, Hogan DE. Imaging after head trauma. Who needs what? *Emerg Med Clin North Am.* Nov 1991;9(4):707-717.

[9] Vollmer DG, Dacey RG, Jr. The management of mild and moderate head injuries. *Neurosurg Clin N Am.* Apr 1991;2(2):437-455.

[10] Langlois JA, Rutland-Brown W, Thomas KE. *Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations, and Deaths.* Atlanta: Division of Injury and Disability Outcomes and Programs. National Center for Injury Prevention and Control. CDC; October 2004.

[11] TBI State Demonstration Grants. *J Head Trauma Rehabil.* Feb 2000;15(1):750-760.

[12] Thurman DJ. Epidemiology and Economics of Head Trauma. *Head Trauma: Basic Preclinical and Clinical Directions.* New York: Wiley-Liss; 2001:327-347.

[13] Stein SC, Fabbri A, Servadei F, Glick HA. A critical comparison of clinical decision instruments for computed tomographic scanning in mild closed traumatic brain injury in adolescents and adults. *Ann Emerg Med.* Feb 2009;53(2):180-188.

[14] Millis SR, Rosenthal M, Novack TA, et al. Long-term neuropsychological outcome after traumatic brain injury. *J Head Trauma Rehabil.* Aug 2001;16(4):343-355.

[15] Alves W, Macciocchi S, Barth JT. Postconcussive Symptoms After Uncomplicated Mild Head Injury. *J Head Trauma Rehabil.* 1993;8(3):48-59.

[16] Rimel RW, Giordani B, Barth JT, Boll TJ, Jane JA. Disability caused by minor head injury. *Neurosurgery.* Sep 1981;9(3):221-228.

[17] Alexander MP. Mild traumatic brain injury: pathophysiology, natural history, and clinical management. *Neurology.* 1995;45(7):1253-1260.

[18] Barth JT, Macciocchi SN, Giordani B, Rimel R, Jane JA, Boll TJ. Neuropsychological sequelae of minor head injury. *Neurosurgery.* Nov 1983;13(5):529-533.

[19] Kennedy RE, Livingston L, Marwitz JH, Gueck S, Kreutzer JS, Sander AM. Complicated mild traumatic brain injury on the inpatient rehabilitation unit: a multicenter analysis. *J Head Trauma Rehabil.* May-Jun 2006;21(3):260-271.

[20] Kennedy JE, Lumpkin RJ, Grissom JR. A survey of mild traumatic brain injury treatment in the emergency room and primary care medical clinics. *Mil Med.* Jun 2006;171(6):516-521.
[21] Narayan RK, Michel ME, Ansell B, et al. Clinical trials in head injury. *J Neurotrauma*. May 2002;19(5):503-557.
[22] Saatman KE, Duhaime AC, Bullock R, Maas AI, Valadka A, Manley GT. Classification of traumatic brain injury for targeted therapies. *J Neurotrauma*. Jul 2008;25(7):719-738.
[23] Doppenberg EM, Choi SC, Bullock R. Clinical trials in traumatic brain injury: lessons for the future. *J Neurosurg Anesthesiol*. Jan 2004;16(1):87-94.
[24] Maas AI, Hukkelhoven CW, Marshall LF, Steyerberg EW. Prediction of outcome in traumatic brain injury with computed tomographic characteristics: a comparison between the computed tomographic classification and combinations of computed tomographic predictors. *Neurosurgery*. Dec 2005;57(6):1173-1182; discussion 1173-1182.
[25] Kesler ea. APECT, MR and quantitative MR imaging: correlates with neuropsychological. *Brain Injury*. 2000;14:851-857.
[26] Jagoda AS, Bazarian JJ, Bruns JJ, Jr., et al. Clinical policy: neuroimaging and decisionmaking in adult mild traumatic brain injury in the acute setting. *Ann Emerg Med*. Dec 2008;52(6):714-748.
[27] Wardlaw JM, Keir SL, Seymour J, et al. What is the best imaging strategy for acute stroke? *Health Technol Assess*. Jan 2004;8(1):iii, ix-x, 1-180.
[28] Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. *N Engl J Med*. Nov 29 2007;357(22):2277-2284.
[29] Fayngersh V, Passero M. Estimating radiation risk from computed tomography scanning. *Lung*. May-Jun 2009;187(3):143-148.
[30] Hall EJ, Brenner DJ. Cancer risks from diagnostic radiology. *Br J Radiol*. May 2008;81(965):362-378.
[31] Heilbrun ME, Chew FS, Tansavatdi KR, Tooze JA. The role of negative CT of the abdomen and pelvis in the decision to admit adults from the emergency department after blunt trauma. *J Am Coll Radiol*. Nov 2005;2(11):889-895.
[32] Livingston DH, Loder PA, Koziol J, Hunt CD. The use of CT scanning to triage patients requiring admission following minimal head injury. *J Trauma*. Apr 1991;31(4):483-487; discussion 487-489.
[33] Berrington de Gonzalez A, Mahesh M, Kim KP, et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. *Arch Intern Med*. Dec 14 2009;169(22):2071-2077.
[34] Schwartz DT. Counter-Point: Are We Really Ordering Too Many CT Scans? *West J Emerg Med*. May 2008;9(2):120-122.
[35] Stiell IG, Wells GA, Vandemheen K, et al. Variation in ED use of computed tomography for patients with minor head injury. *Ann Emerg Med*. Jul 1997;30(1):14-22.
[36] Choudhary J, Grant SG. Proteomics in post-genomic neuroscience: the end of the beginning. *Nat Neurosci*. May 2004;7(5):440-445.
[37] Collins MO, Yu L, Coba MP, et al. Proteomic analysis of in vivo phosphorylated synaptic proteins. *J Biol Chem*. Feb 18 2005;280(7):5972-5982.
[38] Choi SC, Bullock R. Design and statistical issues in multicenter trials of severe head injury. *Neurological Research*. 2001;Mar-Apr(23(2-3)):190-192.
[39] Doppenberg EM, Choi SC, Bullock R. Clinical trials in traumatic brain injury. What can we learn from previous studies? *Ann N Y Acad Sci*. Oct 15 1997;825:305-322.
[40] Denslow N, Michel ME, Temple MD, Hsu CY, Saatman K, Hayes RL. Application of proteomics technology to the field of neurotrauma. *J Neurotrauma.* May 2003;20(5):401-407.

[41] Wang KK, Ottens AK, Liu MC, et al. Proteomic identification of biomarkers of traumatic brain injury. *Expert Rev Proteomics.* Aug 2005;2(4):603-614.

[42] Pineda JA, Lewis SB, Valadka AB, et al. Clinical significance of alphaII-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. *J Neurotrauma.* Feb 2007;24(2):354-366.

[43] Brophy GM, Pineda JA, Papa L, et al. alphaII-Spectrin breakdown product cerebrospinal fluid exposure metrics suggest differences in cellular injury mechanisms after severe traumatic brain injury. *J Neurotrauma.* Apr 2009;26(4):471-479.

[44] Papa L, Akinyi L, Liu MC, et al. Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. *Crit Care Med.* Jan 2010;38(1):138-144.

[45] Missler U. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. *Stroke.* 1997;28:1956-1960.

[46] Ytrebo LM NG, Korvald C, et al. Renal elimination of protein S-100beta in pigs with acute encephalopathy. *Scand J Clin Lab Invest.* 2001;61:217-225.

[47] Jonsson H JP, Hoglund P, Alling C, Blomquist S. The elimination of S-100b and renal function after cardiac surgery. *J Cardiothorac Vasc Aneth.* 2000;14:698-701.

[48] Usui A KK, Abe T, Murase M, Tanaka M, Takeuchi E. S-100a0 protein in blood and urine during open-heart surgery. *Clin Chem.* 1989;35:1942-1944.

[49] Raabe A, Grolms C, Seifert V. Serum markers of brain damage and outcome prediction in patients after severe head injury. *Br J Neurosurg.* 1999;13(1):56-59.

[50] Haimoto HH, S; Kato, K. Differential distribution of immunoreactive S100-a and S100-b proteins in normal nonnervous human tissues. *Lab Invest.* 1987;57:489-498.

[51] Woertgen C, Rothoerl RD, Holzschuh M, Metz C, Brawanski A. Comparison of serial S-100 and NSE serum measurements after severe head injury. *Acta Neurochir (Wien).* 1997;139(12):1161-1164; discussion 1165.

[52] Romner B, Ingebrigtsen T, Kongstad P, Borgesen SE. Traumatic brain damage: serum S-100 protein measurements related to neuroradiological findings. *J Neurotrauma.* Aug 2000;17(8):641-647.

[53] Korfias S, Stranjalis G, Boviatis E, et al. Serum S-100B protein monitoring in patients with severe traumatic brain injury. *Intensive Care Med.* Feb 2007;33(2):255-260.

[54] Vos PE, Jacobs B, Andriessen TM, et al. GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. *Neurology.* Nov 16 2010;75(20):1786-1793.

[55] Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Kochanek PM. Serum S100B concentrations are increased after closed head injury in children: a preliminary study. *J Neurotrauma.* Nov 2002;19(11):1405-1409.

[56] BW M. A soluble protein characteristic of the nervous system. *Biochem Biophys Res Commun.* 1965;19:739-744.

[57] Donato R. Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. *Biochim Biophys Acta.* 1999;1450:191-231.

[58] Cooper E. Neuron-specific enolase. *Int J Biol Markers.* 1994(4):205-210.
[59] Yamazaki Y, Yada K, Morii S, Kitahara T, Ohwada T. Diagnostic significance of serum neuron-specific enolase and myelin basic protein assay in patients with acute head injury. Surg Neurol. Mar 1995;43(3):267-270; discussion 270-261.

[60] de Kruijk JR, Leffers P, Menheere PP, Meerhoff S, Twijnstra A. S-100B and neuron-specific enolase in serum of mild traumatic brain injury patients. A comparison with health controls. Acta Neurol Scand. Mar 2001;103(3):175-179.

[61] Raabe A, Grolms C, Seifert V. Serum markers of brain damage and outcome prediction in patients after severe head injury. Br J Neurosurg. Feb 1999;13(1):56-59.

[62] Ross SA, Cunningham RT, Johnston CF, Rowlands BJ. Neuron-specific enolase as an aid to outcome prediction in head injury. Br J Neurosurg. Oct 1996;10(5):471-476.

[63] Naeimi ZS, Weinhofer A, Sarahrudi K, Heinz T, Vecsei V. Predictive value of S-100B protein and neuron specific-enolase as markers of traumatic brain damage in clinical use. Brain Inj. May 2006;20(5):463-468.

[64] Berger RP, Adelson PD, Pierce MC, Dulani T, Cassidy LD, Kochanek PM. Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. J Neurosurg. Jul 2005;103(1 Suppl):61-68.

[65] Berger RP, Beers SR, Richichi R, Wiesman D, Adelson PD. Serum biomarker concentrations and outcome after pediatric traumatic brain injury. J Neurotrauma. Dec 2007;24(12):1793-1801.

[66] Beers SR, Berger RP, Adelson PD. Neurocognitive outcome and serum biomarkers in inflicted versus non-inflicted traumatic brain injury in young children. J Neurotrauma. Jan 2007;24(1):97-105.

[67] Piazza O, Storti MP, Cotena S, et al. S100B is not a reliable prognostic index in paediatric TBI. Pediatr Neurosurg. 2007;43(4):258-264.

[68] Martens P. Serum neuron-specific enolase as a prognostic marker for irreversible brain damage in comatose cardiac arrest survivors. Acad Emerg Med. 1996;3:126-131.

[69] Rainey T, Lesko M, Sacho R, Lecky F, Childs C. Predicting outcome after severe traumatic brain injury using the serum S100B biomarker: results using a single (24h) time-point. Resuscitation. Mar 2009;80(3):341-345.

[70] Bazarian JJ, Zemlan FP, Mookerjee S, Stigbrand T. Serum S-100B and cleaved-tau are poor predictors of long-term outcome after mild traumatic brain injury. Brain Inj. Jun 2006;20(7):759-765.

[71] Watt SE, Shores EA, Baguley IJ, Dorsch N, Fearnside MR. Protein S-100 and neuropsychological functioning following severe traumatic brain injury. Brain Inj. Sep 2006;20(10):1007-1017.

[72] Morochovic R, Racz O, Kitka M, et al. Serum S100B protein in early management of patients after mild traumatic brain injury. Eur J Neurol. Oct 2009;16(10):1112-1117.

[73] Dirnagl U CI, and Moskowitz MA. Pathology of ischaemic stroke: an integrated view. TINS. 1999;22(9):391-397.

[74] Laskowitz ea. Serum Markers of Cerebral Ischemia. Journal of Stroke and Cerebrovascular Diseases. 1998;7(4 (July-August)):234-241.

[75] Roine ea. Neurological outcome after out-of-hospital cardiac arrest. Prediction by cerebrospinal fluid enzyme analysis. Arch Neurol. 1989;46:753-756.
[76] Xiong H, Liang WL, Wu XR. [Pathophysiological alterations in cultured astrocytes exposed to hypoxia/reoxygenation]. Sheng Li Ke Xue Jin Zhan. Jul 2000;31(3):217-221.

[77] Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull. 1995;37(4):417-429.

[78] Ingebrigtsen T, Romner B. Management of minor head injuries in hospitals in Norway. Acta Neurol Scand. Jan 1997;95(1):51-55.

[79] Waterloo K, Ingebrigtsen T, Romner B. Neuropsychological function in patients with increased serum levels of protein S-100 after minor head injury. Acta Neurochir (Wien). 1997;139(1):26-31; discussion 31-22.

[80] Ingebrigtsen T, Romner B. Serial S-100 protein serum measurements related to early magnetic resonance imaging after minor head injury. Case report. J Neurosurg. Nov 1996;85(5):945-948.

[81] Ingebrigtsen T, Waterloo K, Jacobsen EA, Langbakk B, Romner B. Traumatic brain damage in minor head injury: relation of serum S-100 protein measurements to magnetic resonance imaging and neurobehavioral outcome. Neurosurgery. Sep 1999;45(3):468-475; discussion 475-466.

[82] Ingebrigtsen T, Romner B, Marup-Jensen S, et al. The clinical value of serum S-100 protein measurements in minor head injury: a Scandinavian multicentre study. Brain Inj. Dec 2000;14(12):1047-1055.

[83] Muller K, Townend W, Biasca N, et al. S100B serum level predicts computed tomography findings after minor head injury. J Trauma. Jun 2007;62(6):1452-1456.

[84] Biberthaler P, Linsenmeier U, Pfeifer KJ, et al. Serum S-100B concentration provides additional information for the indication of computed tomography in patients after minor head injury: a prospective multicenter study. Shock. May 2006;25(5):446-453.

[85] Phillips JP, Jones HM, Hitchcock R, Adama N, Thompson RJ. Radioimmunoassay of serum creatine kinase BB as index of brain damage after head injury. Br Med J. Sep 20 1980;281(6243):777-779.

[86] Rothoerl RD, Woertgen C, Holzschuh M, Metz C, Brawanski A. S-100 serum levels after minor and major head injury. J Trauma. Oct 1998;45(4):765-767.

[87] Bechtel K, Frasure S, Marshall C, Dziura J, Simpson C. Relationship of serum S100B levels and intracranial injury in children with closed head trauma. Pediatrics. Oct 2009;124(4):e697-704.

[88] Rothoerl RD, Woertgen C. High serum S100B levels for trauma patients without head injuries. Neurosurgery. Dec 2001;49(6):1490-1491; author reply 1492-1493.

[89] Romner B, Ingebrigtsen T. High serum S100B levels for trauma patients without head injuries. Neurosurgery. Dec 2001;49(6):1490; author reply 1492-1493.

[90] Anderson RE, Hansson LO, Nilsson O, Djilai-Merzoug R, Settergen G. High serum S100B levels for trauma patients without head injuries. Neurosurgery. 2001;49(5):1272-1273.

[91] Skogseid IM, Nordby HK, Urdal P, Paus E, Lilleaas F. Increased serum creatine kinase BB and neuron specific enolase following head injury indicates brain damage. Acta Neurochir (Wien). 1992;115(3-4):106-111.

[92] Schmechel D, Marangos PJ, Brightman M. Neurone-specific enolase is a molecular marker for peripheral and central neuroendocrine cells. Nature. Dec 21-28 1978;276(5690):834-836.
[93] Ergun R, Bostanci U, Akdemir G, et al. Prognostic value of serum neuron-specific enolase levels after head injury. *Neurol Res.* Jul 1998;20(5):418-420.

[94] Varma S, Janeswski KL, Wisniewski SR, et al. F2-isoprostane and neuron-specific enolase in cerebrospinal fluid after severe traumatic brain injury in infants and children. *J Neurotrauma.* Aug 2003;20(8):781-786.

[95] Bandyopadhyay S, Hennes H, Gorelick MH, Wells RG, Walsh-Kelly CM. Serum neuron-specific enolase as a predictor of short-term outcome in children with closed traumatic brain injury. *Acad Emerg Med.* Aug 2005;12(8):732-738.

[96] Johnsson P, Blomquist S, Luhrs C, et al. Neuron-specific enolase increases in plasma during and immediately after extracorporeal circulation. *Ann Thorac Surg.* Mar 2000;69(3):750-754.

[97] Kosik KS, Finch EA. MAP2 and tau segregate into dendritic and axonal domains after the elaboration of morphologically distinct neurites: an immunocytochemical study of cultured rat cerebrum. *J Neurosci.* Oct 1987;7(10):3142-3153.

[98] Higuchi M, Lee VM, Trojanowski JQ. Tau and axonopathy in neurodegenerative disorders. *Neuromolecular Med.* 2002;2(2):131-150.

[99] Shaw GJ, Jauch EC, Zemlan FP. Serum cleaved tau protein levels and clinical outcome in adult patients with closed head injury. *Ann Emerg Med.* Mar 2002;39(3):254-257.

[100] Zemlan FP, Jauch EC, Mulchahey JJ, et al. C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome. *Brain Res.* Aug 23 2002;947(1):131-139.

[101] Chatfield DA, Zemlan FP, Day DJ, Menon DK. Discordant temporal patterns of S100beta and cleaved tau protein elevation after head injury: a pilot study. *Br J Neurosurg.* Oct 2002;16(5):471-476.

[102] Goodman SR, Zimmer WE, Clark MB, Zagon IS, Barker JE, Bloom ML. Brain spectrin: of mice and men. *Brain Res Bull.* 1995;36(6):593-606.

[103] Riederer BM, Zagon IS, Goodman SR. Brain spectrin(240/235) and brain spectrin(240/235E): two distinct spectrin subtypes with different locations within mammalian neural cells. *J Cell Biol.* Jun 1986;102(6):2088-2097.

[104] Wang KK, Posmantur R, Nath R, et al. Simultaneous degradation of alphall- and betall-spectrin by caspase 3 (CPP32) in apoptotic cells. *J Biol Chem.* Aug 28 1998;273(35):22490-22497.

[105] McGinn MJ, Kelley BJ, Akinyi L, et al. Biochemical, structural, and biomarker evidence for calpain-mediated cytoskeletal change after diffuse brain injury uncomplicated by contusion. *J Neuropathol Exp Neurol.* Mar 2009;68(3):241-249.

[106] Pike BR, Flint J, Dave JR, et al. Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphall-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. *J Cereb Blood Flow Metab.* Jan 2004;24(1):98-106.

[107] Ringger NC, O’Steen BE, Brabham JG, et al. A novel marker for traumatic brain injury: CSF alphall-spectrin breakdown product levels. *J Neurotrauma.* Oct 2004;21(10):1443-1456.

[108] Cardali S, Maugeri R. Detection of alphall-spectrin and breakdown products in humans after severe traumatic brain injury. *J Neurosurg Sci.* Jun 2006;50(2):25-31.

[109] Papa L, D’Avella D, Aguennouz M, et al. Detection of Alpha-II Spectrin And Breakdown Products In Humans After Severe Traumatic Brain Injury [abstract]. *Acad Emerg Med.* May 2004;11(5).
Papa L, Lewis SB, Heaton S, et al. Predicting Early Outcome Using Alpha-II Spectrin Breakdown Products in Human CSF After Severe Traumatic Brain Injury [abstract]. Acad Emerg Med. May 2006;13(5 (Suppl 1)).

Papa L, Pineda J, Wang KKW, et al. Levels of Alpha-II Spectrin Breakdown Products in Human CSF and Outcome After Severe Traumatic Brain Injury [abstract]. Acad Emerg Med. May 2005;12(5 (Suppl 1)).

Farkas O, Polgar B, Szekeres-Bartho J, Doczi T, Povlishock JT, Buki A. Spectrin breakdown products in the cerebrospinal fluid in severe head injury--preliminary observations. Acta Neurochir (Wien). Aug 2005;147(8):855-861.

Mondello S, Robicsek SA, Gabrielli A, et al. alphaII-spectrin breakdown products (SBDPs): diagnosis and outcome in severe traumatic brain injury patients. J Neurotrauma. Jul 2010;27(7):1203-1213.

Jackson P, Thompson RJ. The demonstration of new human brain-specific proteins by high-resolution two-dimensional polyacrylamide gel electrophoresis. J Neurol Sci. Mar 1981;49(3):429-438.

Tongaonkar P, Chen L, Lamberton D, Ko B, Madura K. Evidence for an interaction between ubiquitin-conjugating enzymes and the 26S proteasome. Mol Cell Biol. Jul 2000;20(13):4691-4698.

Gong B, Leznik E. The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders. Drug News Perspect. Jul-Aug 2007;20(6):365-370.

Kobeissy FH, Ottens AK, Zhang Z, et al. Novel differential neuroproteomics analysis of traumatic brain injury in rats. Mol Cell Proteomics. Oct 2006;5(10):1887-1898.

Liu MC, Akinyi L, Scharf D, et al. Ubiquitin C-terminal hydrolase-L1 as a biomarker for ischemic and traumatic brain injury in rats. Eur J Neurosci. Feb 2010;31(4):722-732.

Siman R, Toraskar N, Dang A, et al. A panel of neuron-enriched proteins as markers for traumatic brain injury in humans. J Neurotrauma. Nov 2009;26(11):1867-1877.

Brophy G, Mondello S, Papa L, et al. Biokinetic Analysis of Ubiquitin C-Terminal Hydrolase-L1 (Uch-L1) in Severe Traumatic Brain Injury Patient Biofluids. J Neurotrauma. Feb 10.

Papa L, Lewis LM, Falk JL, et al. Serum levels of UCH-L1 distinguishes mild and moderate traumatic brain injury from trauma controls and is associated with lesions on computed tomography [abstract]. J Neurotrauma. 2011;28(July):A1-A134.

Eng LF, Vanderhaeghen JJ, Bignami A, Gerstl B. An acidic protein isolated from fibrous astrocytes. Brain Res. May 7 1971;28(2):351-354.

Duchen LW. General pathology of neurons and neuroglia. In: Adams JA, Corsellis JAN, Duchen LW, eds. Greenfield’s Neuropathology. London: Edward Arnold; 1984:1-52.

Baydas G, Nedzvetskii VS, Tuzcu M, Yasar A, Kirichenko SV. Increase of glial fibrillary acidic protein and S-100B in hippocampus and cortex of diabetic rats: effects of vitamin E. Eur J Pharmacol. Feb 21 2003;462(1-3):67-71.

Mouser PE, Head E, Ha KH, Rohn TT. Caspase-mediated cleavage of glial fibrillary acidic protein within degenerating astrocytes of the Alzheimer’s disease brain. Am J Pathol. Mar 2006;168(3):936-946.

Herrmann M, Vos P, Wunderlich MT, de Bruijn CH, Lamers KJ. Release of glial tissue-specific proteins after acute stroke: A comparative analysis of serum concentrations.
of protein S-100B and glial fibrillary acidic protein. *Stroke.* Nov 2000;31(11):2670-2677.

[127] Missler U, Wiesmann M, Wittmann M, Magerkurth O, Hagenstrom H. Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. *Clin Chem.* Jan 1999;45(1):138-141.

[128] Pelinka LE, Kroepl A, Leixnering M, Buchinger W, Raabe A, Redl H. GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. *J Neurotrauma.* Nov 2004;21(11):1553-1561.

[129] Pelinka LE, Kroepl A, Schmidhammer R, et al. Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. *J Trauma.* Nov 2004;57(5):1006-1012.

[130] van Geel WJ, de Reus HP, Nijzing H, Verbeek MM, Vos PE, Lamers KJ. Measurement of glial fibrillary acidic protein in blood: an analytical method. *Clin Chim Acta.* Dec 2002;326(1-2):151-154.

[131] Nylen K, Ost M, Csajbok LZ, et al. Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. *J Neurol Sci.* Jan 15 2006;240(1-2):85-91.

[132] Papa L, Akinyi L, Demery J, et al. Levels of Serum GFAP Are Associated With Severity Of Injury In Patients With Mild And Moderate Traumatic Brain Injury [abstract]. *Acad Emerg Med.* May 2008;15(5):Suppl.

[133] Papa L, Lewis LM, Falk JL, et al. Elevated Levels of Serum Glial Fibrillary Acidic Protein Breakdown Products in Mild and Moderate Traumatic Brain Injury Are Associated With Intracranial Lesions and Neurosurgical Intervention. *Ann Emerg Med.* Nov 7 2011.

[134] Kochanek PM, Berger RP, Bayr H, Wagner AK, Jenkins LW, Clark RS. Biomarkers of primary and evolving damage in traumatic and ischemic brain injury: diagnosis, prognosis, probing mechanisms, and therapeutic decision making. *Curr Opin Crit Care.* Apr 2008;14(2):135-141.

[135] Papa L, Robinson G, Oli M, et al. Use of Biomarkers for Diagnosis and Management of Traumatic Brain Injury Patients. *Expert Opinion on Medical Diagnostics.* 2008;2(8):937-945.

[136] Stiell IG, Wells GA. Methodologic standards for the development of clinical decision rules in emergency medicine. *Ann Emerg Med.* Apr 1999;33(4):437-447.

[137] Laupacis A, Sekar N, Stiell IG. Clinical prediction rules. A review and suggested modifications of methodological standards. *Jama.* Feb 12 1997;277(6):488-494.

[138] Maas AI, Marmarou A, Murray GD, Teasdale SG, Steyerberg EW. Prognosis and clinical trial design in traumatic brain injury: the IMPACT study. *J Neurotrauma.* Feb 2007;24(2):232-238.

[139] Cantu RC. Return to play guidelines after a head injury. *Clin Sports Med.* Jan 1998;17(1):45-60.

[140] Erlanger DM, Kutner KC, Barth JT, Barnes R. Neuropsychology of sports-related head injury: Dementia Pugilistica to Post Concussion Syndrome. *Clin Neuropsychol.* May 1999;13(2):193-209.

[141] McCrory PR, Berkovic SF. Second impact syndrome. *Neurology.* Mar 1998;50(3):677-683.

[142] Carey ME. Analysis of wounds incurred by U.S. Army Seventh Corps personnel treated in Corps hospitals during Operation Desert Storm, February 20 to March 10, 1991. *J Trauma.* Mar 1996;40(3 Suppl):S165-169.
[143] Sapsford W. Penetrating brain injury in military conflict: does it merit more research? *J R Army Med Corps.* Mar 2003;149(1):5-14.

[144] Okie S. Traumatic brain injury in the war zone. *N Engl J Med.* May 19 2005;352(20):2043-2047.

[145] Warden D. Blast Injury. [http://www.dvbic.org/cms.php?p=Blast_injury]. Accessed April 9, 2008.
Biomedical research has entered a new era of characterizing a disease or a protein on a global scale. In the post-genomic era, Proteomics now plays an increasingly important role in dissecting molecular functions of proteins and discovering biomarkers in human diseases. Mass spectrometry, two-dimensional gel electrophoresis, and high-density antibody and protein arrays are some of the most commonly used methods in the Proteomics field. This book covers four important and diverse areas of current proteomic research: Proteomic Discovery of Disease Biomarkers, Proteomic Analysis of Protein Functions, Proteomic Approaches to Dissecting Disease Processes, and Organelles and Secretome Proteomics. We believe that clinicians, students and laboratory researchers who are interested in Proteomics and its applications in the biomedical field will find this book useful and enlightening. The use of proteomic methods in studying proteins in various human diseases has become an essential part of biomedical research.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

Linda Papa (2012). Exploring the Role of Biomarkers for the Diagnosis and Management of Traumatic Brain Injury Patients, Proteomics - Human Diseases and Protein Functions, Prof. Tsz Kwong Man (Ed.), ISBN: 978-953-307-832-8, InTech, Available from: http://www.intechopen.com/books/proteomics-human-diseases-and-protein-functions/exploring-the-role-of-biomarkers-for-the-diagnosis-and-management-of-traumatic-brain-injury-patients